

K080654

**510(k) Premarket Notification Submission:**

**MAY - 8 2008**

**Summary of Safety and Effectiveness for PAJUNK®'s Kit for balloon aided laparoscopy**

**Date of Preparation: April 12<sup>th</sup> 2008**

**Submitter Information/ production site:**

Pajunk GmbH  
Karl-Hall-Strasse 01  
78187 Geisingen  
Germany  
Fon: +49(0)7704-9291-586  
Fax: +49(0)7704-9291-605

Establishment Registration Number: **9611612**

**Contact:**

Christian Quass, Director Regulatory Affairs  
Fon: +49(0)7704-9291-586  
Fax: +49(0)7704-9291-605  
E-Mail: christian.quass@pajunk.com

**USA Contact:**

Pajunk Medical Systems  
German American Trade Center  
5126 South Royal Atlanta Drive  
30084 Tucker, Georgia  
USA

**Contact**

Stefan Dayagi  
Fon: +01(0)770-493-9305

E-Mail: stefan.dayagi@pajunk-usa.com

**Contract Sterilizer:**

STERIGENICS GERMANY GMBH  
Rheingaustrasse 190-196  
65203 Wiesbaden, GERMANY

**Registration Number:** 3002807090

**Operations:** Contract Sterilizer

**Status:** Active

**Device Information:**

Device Name:	<b>PAJUNK®'s Kit for balloon aided laparoscopy</b>
Trade Names:	<b>Balloon Laparoscopes</b>
Common Name:	<b>Kit, balloon, trocar, port</b>
Classification Name:	<b>Endoscope and accessories</b>
Classification Reference:	<b>21 CFR §876.1500, April 1, 2007</b>
Establishment Registration Number:	<b>9611612</b>
Regulatory Class:	<b>II</b>
Product Code:	<b>GCJ</b>
Panel:	<b>Gastroenterology/Urology</b>
Predicate Devices:	<b>1. K012771 Trocar Sleeve and accessories – PAJUNK® 2. K063528 TrokaSys – PAJUNK®</b>

### **Device Description:**

The kit provides a common port with trocar and valve closure (for gaining access for minimal invasive surgery) packed in a separate bag within the sterilized unit and a rigid balloon guidance with obturator and filling syringe (for insertion of the endoscopic visualisation device) packed in another separate bag. Both units are available separately and as a procedure unit.

It is especially intended for diagnostics and aftercare in minimal invasive procedures.

Due to the length of the balloon guidance and the clinical practice there is no need to create a pneumoperitoneum via insufflation.

The port may be left in place for up to 10 days with the seal closure trocar in place.

The kit is sterile and intended for single use.

### **Indications for use:**

**PAJUNK®'s Kit for balloon aided laparoscopy** is intended for making incisions into the patient's body to allow insertion of endoscopes and endoscopic accessories during general and minimal invasive surgical procedures.

### **Additional Claims**

It is especially intended for diagnostics and aftercare.

Due to the length of the balloon guidance and the clinical practice there is no need to create a pneumoperitoneum via insufflation.

The port may be left in place for up to 30 days.

### **Predicate Devices:**

**PAJUNK®'s Kit for balloon aided laparoscopy**, the subject device of this submission, combines technical features of PAJUNK®'s devices already approved for market. Predicate devices with identical or at least similar indications of use are:

1. K012771 Trocar Sleeve and accessories (balloon systems), PAJUNK®
2. K063528 TrokaSys, PAJUNK®

While the predicate devices are indicated for minimal invasive procedures the subject device is indicated for inserting and guiding optical endoscopes for aftercare and diagnostics. The detailed discussion of substantial equivalence can be found in Section 12 of this submission.

### **Sterilization**

The sterilization process is the same as that used for all PAJUNK® Products already cleared for market. It has been validated for double-bag packages with the balloon systems and the disposable trocars TrokaSys, predicate devices of this submission.

**Technology Characteristics:**

The Kit consists of the following components arranged in two bags for two steps in procedure:

Bag 01	Port
	Trocar
	Seal closure trocar
Bag 02	Balloon guidance
	Obturator
	Filling syringe (30ml)

**Conclusion:**

The comparison between the predicate devices and the proposed devices in section 12 of this submission as well as the validated sterilization process and biocompatibility data demonstrates that the proposed Kit is substantially equivalent to the predicate devices and safe and effective. The optional use of optical devices (image giving endoscopes) in order to monitor the procedure and to conduct manually operated interventions under sight/ view are at least as safe and effective as common techniques are, actually this is intended to enhance safety and effectiveness..



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**MAY - 8 2008**

Pajunk GmbH Medizintechnologie  
% Christian Quass  
Director, Regulatory Affairs  
Karl-Hall-Strasse 01  
78187 Geisingen, Germany

Re: K080654

Trade/Device Name: PAJUNK®'s Kit for balloon aided laparoscopy  
Regulation Number: 21 CFR 876.1500  
Regulation Name: Endoscope and accessories  
Regulatory Class: II  
Product Code: GCJ  
Dated: April 21, 2008  
Received: April 23, 2008

Dear Christian Quass:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", with a stylized flourish at the end.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Indications for use

510(k) Number:

K080654

Device Name:

PAJUNK®'s Kit for balloon aided laparoscopy

Indications for Use:

PAJUNK®'s Kit for balloon aided laparoscopy is intended for making incisions into the patients body to allow insertion of endoscopes and endoscopic accessories during general and minimal invasive surgical procedures.

Prescription Use   X    
(Per 21 CFR 801.109)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Neil R.P. Ozul for sign  
(Division Sign-Off)  
Division of General, Restorative,  
and Neurological Devices

510(k) Number K080654